Chengjun Sui

2.6k total citations
58 papers, 1.5k citations indexed

About

Chengjun Sui is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Chengjun Sui has authored 58 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 23 papers in Cancer Research and 22 papers in Surgery. Recurrent topics in Chengjun Sui's work include Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (17 papers) and MicroRNA in disease regulation (13 papers). Chengjun Sui is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (17 papers) and MicroRNA in disease regulation (13 papers). Chengjun Sui collaborates with scholars based in China, Italy and United States. Chengjun Sui's co-authors include Yanming Zhou, Jiamei Yang, Weifeng Shen, Jiamei Yang, Jiongjiong Lu, Binghua Dai, Zhengfeng Yin, Bin Li, Geng Li and Shuangjia Wang and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Chengjun Sui

54 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chengjun Sui China 23 679 625 495 449 362 58 1.5k
Shunli Shen China 22 434 0.6× 370 0.6× 508 1.0× 336 0.7× 480 1.3× 58 1.4k
Stefania Brozzetti Italy 21 586 0.9× 393 0.6× 468 0.9× 424 0.9× 337 0.9× 50 1.6k
Dousheng Bai China 22 531 0.8× 317 0.5× 329 0.7× 339 0.8× 401 1.1× 91 1.3k
Ye Lin China 21 790 1.2× 674 1.1× 352 0.7× 300 0.7× 152 0.4× 59 1.5k
Lijian Liang China 23 529 0.8× 325 0.5× 489 1.0× 512 1.1× 407 1.1× 74 1.4k
Yunlong Cui China 18 462 0.7× 346 0.6× 287 0.6× 262 0.6× 297 0.8× 52 1.1k
Caterina Vivaldi Italy 18 346 0.5× 403 0.6× 760 1.5× 403 0.9× 207 0.6× 101 1.3k
Weikai Xiao China 18 425 0.6× 473 0.8× 477 1.0× 114 0.3× 213 0.6× 37 1.1k
Kunlin Xie China 19 827 1.2× 635 1.0× 293 0.6× 196 0.4× 152 0.4× 46 1.3k
Hajime Takatori Japan 17 669 1.0× 528 0.8× 278 0.6× 546 1.2× 392 1.1× 58 1.7k

Countries citing papers authored by Chengjun Sui

Since Specialization
Citations

This map shows the geographic impact of Chengjun Sui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengjun Sui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengjun Sui more than expected).

Fields of papers citing papers by Chengjun Sui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengjun Sui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengjun Sui. The network helps show where Chengjun Sui may publish in the future.

Co-authorship network of co-authors of Chengjun Sui

This figure shows the co-authorship network connecting the top 25 collaborators of Chengjun Sui. A scholar is included among the top collaborators of Chengjun Sui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengjun Sui. Chengjun Sui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Chunhua, Li Li, Chengjun Sui, et al.. (2025). Prognostic value of the site, depth, and infection/ischemia classification system in diabetic foot ulcers: a retrospective cohort study. Scientific Reports. 15(1). 27003–27003.
3.
Sui, Chengjun, Jiongjiong Lu, Kui Wang, et al.. (2024). Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study. Frontiers in Immunology. 15. 1463574–1463574. 4 indexed citations
4.
Wang, Yizhou, Haoyu Li, Xiaofeng Zhang, et al.. (2024). Identification of SPP1+ macrophages in promoting cancer stemness via vitronectin and CCL15 signals crosstalk in liver cancer. Cancer Letters. 604. 217199–217199. 15 indexed citations
5.
Xue, Jun, S. Yang, Si‐Si Zhang, et al.. (2024). Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy Response. Advanced Science. 11(47). e2309631–e2309631. 2 indexed citations
6.
Wang, Jie, et al.. (2024). Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer. Cancer Reports. 7(2). e1952–e1952. 3 indexed citations
7.
Sui, Chengjun, et al.. (2024). TFAIP6 facilitates hepatocellular carcinoma cell glycolysis through upregulating c-myc/PKM2 axis. Heliyon. 10(10). e30959–e30959. 7 indexed citations
8.
Li, Yong, Li Geng, Weifeng Shen, et al.. (2022). Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. European Journal of Cancer. 166. 176–184. 36 indexed citations
9.
Han, Hong, Qian Tao, Xiang Zhu, et al.. (2021). Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway. Frontiers in Pharmacology. 12. 656697–656697. 17 indexed citations
10.
Xu, Xiaoyong, Xinwei Jiang, Qiang Fei, et al.. (2020). <p>Long Non-Coding RNA SNHG14 Contributes to the Development of Hepatocellular Carcinoma via Sponging miR-217</p>. OncoTargets and Therapy. Volume 13. 4865–4876. 9 indexed citations
11.
Jeong, Seogsong, Yang Ge, Jing Chen, et al.. (2020). Latent Risk Intrahepatic Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach. Frontiers in Oncology. 10. 143–143. 13 indexed citations
12.
Sui, Chengjun, Zhitao Dong, Cheng Yang, et al.. (2019). LncRNA FOXD2‐AS1 as a competitive endogenous RNA against miR‐150‐5p reverses resistance to sorafenib in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. 23(9). 6024–6033. 34 indexed citations
13.
Yang, Cheng, et al.. (2018). lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene. 687. 73–81. 31 indexed citations
14.
Zhou, Yanming, Chengjun Sui, Xiaofeng Zhang, Bin Li, & Jiamei Yang. (2017). Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma. BMC Gastroenterology. 17(1). 25–25. 26 indexed citations
15.
Sui, Chengjun, Yanming Zhou, Weifeng Shen, et al.. (2016). Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429. Journal of Molecular Medicine. 94(11). 1281–1296. 85 indexed citations
16.
Liu, Qu, et al.. (2014). Solitary hepatic lymphangioma: a one-case report. SpringerPlus. 3(1). 314–314. 4 indexed citations
17.
Zhou, Yanming, Xiaofeng Zhang, Bin Li, Chengjun Sui, & Jiamei Yang. (2014). Prognosis After Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma Originating from Non-cirrhotic Liver. Annals of Surgical Oncology. 21(7). 2406–2412. 12 indexed citations
18.
Sui, Chengjun, et al.. (2011). Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi. World Journal of Surgical Oncology. 9(1). 2–2. 24 indexed citations
19.
Zhou, Yanming, Chengjun Sui, Bin Li, et al.. (2011). Safety and efficacy of trisectionectomy for hepatocellular carcinoma. ANZ Journal of Surgery. 81(12). 895–899. 10 indexed citations
20.
Zhou, Yanming, Chengjun Sui, Bin Li, et al.. (2010). Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World Journal of Surgical Oncology. 8(1). 55–55. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunli Shen Breakdown of academic impact, for papers by Stefania Brozzetti Breakdown of academic impact, for papers by Dousheng Bai Breakdown of academic impact, for papers by Ye Lin Breakdown of academic impact, for papers by Lijian Liang Breakdown of academic impact, for papers by Yunlong Cui Breakdown of academic impact, for papers by Caterina Vivaldi Breakdown of academic impact, for papers by Weikai Xiao Breakdown of academic impact, for papers by Kunlin Xie Breakdown of academic impact, for papers by Hajime Takatori
Rankless by CCL
2026